THERAPEUTIC TARGETS INVOLVED IN THE PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS (NASH)

摘要

The present invention relates to methods and compositions for specifically modulating the Hippo pathway transcription factor TAZ (WWTR1), as a therapeutic target for inhibiting or preventing liver conditions including the progression of steatosis-to-NASH in a patient.